Therapeutic potential of Momordica charantia L. var. abbreviata leaves and stem crude extract against acetaminophen-induced liver damage in Sprague-Dawley rats

This study investigated the therapeutic potential of Momordica charantia L. var. abbreviata leaves and stem crude extract in treating acetaminophen-induced liver damage in Sprague-Dawley rats. The research evaluated the effects of liver treatment by analyzing the phytochemical components, histopathological changes, and biochemical markers of liver function, specifically Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT). The experimental study involved administering varying concentrations of the M. charantia L. var. abbreviata extract, namely 200 mg/10 mL, 400 mg/10 mL, and 800 mg/11 mL, to test rats with acetaminophen-induced liver damage. The levels of SGOT and SGPT enzymes were measured. The results indicated that the crude extract contains beneficial phytochemicals, and its administration led to significant reductions in both SGOT and SGPT levels, suggesting a hepatotreatment effect. Histopathological analysis further supported these findings, showing improvements in liver tissue damage that surpassed those observed in the positive control group. The study results indicate that M. charantia L. var. abbreviata shows hepatotreatment potential, offering a promising alternative treatment for acetaminophen-induced liver damage.